Paper Details

  1. Home
  2. Paper Details

Chronic active hepatitis induced by Pazopanib mimicking hypervascular liver metastases in a patient with recurrent soft tissue sarcoma: A case report.

Author: CalvoMarta, De La HuebraIgnacio González, EzpondaAna, IdoateMiguel Ángel, VivasIsabel

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

Pazopanib is a drug used to treat advanced soft tissue sarcoma. It has been shown to help patients live longer without experiencing significant side effects. However, Pazopanib can cause liver problems, including a rare condition where the liver becomes inflamed and develops abnormal growths. These growths can look like cancer, but they are actually caused by the drug. It's important to know about this rare side effect so that doctors don't misdiagnose patients and stop effective treatment too soon.
Paper Details　
Original Abstract of the Article :
Pazopanib is the first multitargeted tyrosine-kinase inhibitor approved for the treatment of patients with advanced non-adipocytic soft tissue sarcoma (STS). It has been demonstrated to improve progression-free survival without impairing health-associated quality of life. However, Pazopanib is assoc...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6096083/

データ提供：米国国立医学図書館（NLM）

Pazopanib: A Double-Edged Sword in the Treatment of Soft Tissue Sarcoma

This case report delves into the complex world of Pazopanib, a multitargeted tyrosine-kinase inhibitor used to treat advanced soft tissue sarcoma (STS). The authors present a unique case of a patient with recurrent STS who developed biopsy-proven Pazopanib-induced chronic active hepatitis. This case highlights the potential hepatotoxicity associated with Pazopanib, particularly its effect on the vascular endothelial growth factor receptor (VEGFR). The authors caution that the liver lesions observed in this patient were indistinguishable from metastases, underscoring the importance of careful monitoring for Pazopanib-related hepatotoxicity to avoid overstaging and premature treatment discontinuation.

Pazopanib: A Powerful Ally with Potential Side Effects

This case report serves as a reminder of the potential side effects of Pazopanib, a medication that can be a powerful ally in the fight against STS. Imagine a brave warrior, Pazopanib, fighting against a formidable foe, STS. While this warrior can inflict significant damage on the enemy, it also carries a risk of collateral damage, in this case, affecting the liver.

Navigating the Landscape of Soft Tissue Sarcoma Treatment

This case report emphasizes the importance of vigilant monitoring for Pazopanib-related side effects, particularly hepatotoxicity. As we navigate the complex landscape of soft tissue sarcoma treatment, we must remain aware of the potential risks and benefits of various therapies.

Dr. Camel's Conclusion

This case report serves as a valuable reminder of the potential hepatotoxicity associated with Pazopanib, a medication used to treat STS. While Pazopanib can be an effective treatment option, careful monitoring for liver dysfunction is crucial to ensure its safe and effective use. As we traverse the desert of cancer treatment, vigilance and awareness are essential for providing optimal patient care.

Date :
  1. Date Completed n.d.
  2. Date Revised 2020-09-30
Further Info :

Pubmed ID

30128026

DOI: Digital Object Identifier

PMC6096083

Related Literature

Article Analysis
・Side Effects of pazopanib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.